Another study identified that the response to gilteritinib and crenolanib among relapsed FLT3mut AML patients is higher in patients with mutations in NPM1 or DNMT3A and particularly in those with both genes mutated [58,59]. Here, NPM1 is linked to acute myeloid leukemia.